Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2013

01-09-2013 | Original Article

Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer

Authors: Anneke Neumann, Helen Hörzer, Nina Hillen, Karin Klingel, Barbara Schmid-Horch, Hans-Jörg Bühring, Hans-Georg Rammensee, Hermann Aebert, Stefan Stevanović

Published in: Cancer Immunology, Immunotherapy | Issue 9/2013

Login to get access

Abstract

Introduction

Lung cancer is the most common cancer worldwide. Every year, as many people die of lung cancer as of breast, colon and rectum cancers combined. Because most patients are being diagnosed in advanced, not resectable stages and therefore have a poor prognosis, there is an urgent need for alternative therapies. Since it has been demonstrated that a high number of tumor- and stromal-infiltrating cytotoxic T cells (CTLs) is associated with an increased disease-specific survival in lung cancer patients, it can be assumed that immunotherapy, e.g. peptide vaccines that are able to induce a CTL response against the tumor, might be a promising approach.

Methods

We analyzed surgically resected lung cancer tissues with respect to HLA class I- and II-presented peptides and gene expression profiles, aiming at the identification of (novel) tumor antigens. In addition, we tested the ability of HLA ligands derived from such antigens to generate a CTL response in healthy donors.

Results

Among 170 HLA ligands characterized, we were able to identify several potential targets for specific CTL recognition and to generate CD8+ T cells which were specific for peptides derived from cyclin D1 or protein-kinase, DNA-activated, catalytic polypeptide and lysed tumor cells loaded with peptide.

Conclusions

This is the first molecular analysis of HLA class I and II ligands ex vivo from human lung cancer tissues which reveals known and novel tumor antigens able to elicit a CTL response.
Appendix
Available only for authorised users
Literature
1.
2.
Passlick B, Pantel K, Kubuschok B, Angstwurm M, Neher A, Thetter O, Schweiberer L, Izbicki JR (1996) Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. Eur J Cancer 32A:141–145PubMedCrossRef
3.
Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M (2007) HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 98:1424–1430PubMedCrossRef
4.
Verdegaal EM, Hoogstraten C, Sandel MH, Kuppen PJ, Brink AA, Claas FH, Gorsira MC, Graadt van Roggen JF, Osanto S (2007) Functional CD8 + T cells infiltrate into nonsmall cell lung carcinoma. Cancer Immunol Immunother 56:587–600PubMedCrossRef
5.
Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14:5220–5227PubMedCrossRef
6.
Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG (1991) Allel-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290–296PubMedCrossRef
7.
Weinzierl AO, Maurer D, Altenberend F, Schneiderhan-Marra N, Klingel K, Schoor O et al (2008) A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays. Cancer Res 68:2447–2454PubMedCrossRef
8.
Weinzierl AO, Lemmel C, Schoor O, Müller M, Krüger T, Wernet D et al (2007) Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics 6:102–113PubMed
9.
Krüger T, Schoor O, Lemmel C, Kraemer B, Reichle C, Dengjel J et al (2005) Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 54:826–836PubMedCrossRef
10.
Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94–96PubMedCrossRef
11.
Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W (1998) Her-2/neu derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58:732–736PubMed
12.
Stickel JS, Stickel N, Hennenlotter J, Klingel K, Stenzl A, Rammensee HG, Stevanovic S (2011) Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation. BMC Urol 11:1–11PubMedCrossRef
13.
Shetty V, Sinnathamby G, Nickens Z, Shah P, Hafner J, Mariello L et al (2011) MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. J Proteomics 74:728–743PubMedCrossRef
14.
Abe H, Kamai T, Shirataki H, Oyama T, Arai K, Yoshida K (2008) High expression of Ran GTPase is associated with local invasion and metastasis of human clear cell renal cell carcinoma. Int J Cancer 122:2391–2397PubMedCrossRef
15.
Ueno T, Linder S, Elmberger G (2003) Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer 88:1229–1233PubMedCrossRef
16.
Gsur A, Zidek T, Schnattinger K, Feik E, Haidinger G, Hollaus P et al (2003) Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. Br J Cancer 89:702–706PubMedCrossRef
17.
Hiruma Y, Honjo T, Jelinek DF, Windle JJ, Shin J, Roodman GD, Kurihara N (2009) Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood 113:4894–4902PubMedCrossRef
18.
Volm M, Koomägi R (2000) Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer 82:1747–1754PubMedCrossRef
19.
Yu Q, Geng Y, Sicinski P (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017–1021PubMedCrossRef
20.
LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W (2004) Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 34:1513–1525PubMedCrossRef
21.
Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F et al (2006) Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 12:4163–4170PubMedCrossRef
22.
Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM (2006) Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119:599–607PubMedCrossRef
23.
Azuma K, Sasada T, Takedatsu H, Shomura H, Koga M, Maeda Y et al (2004) Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients. Clin Cancer Res 10:6695–6702PubMedCrossRef
24.
Bishop JA, Sharma R, Illei PB (2010) Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 41:20–25PubMedCrossRef
25.
Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945–954PubMed
26.
Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR (2004) STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA 101:1714–1719PubMedCrossRef
27.
Hui Z, Tretiakova M, Zhang Z, Li Y, Wang X, Zhu JX et al (2009) Radiosensitization by inhibiting STAT1 in renal cell carcinoma. Int J Radiat Oncol Biol Phys 73:288–295PubMedCrossRef
28.
Terry G, Ho L, Londesborough P, Duggan C, Hanby A, Cuzick J (2007) The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. Br J Cancer 96:110–117PubMedCrossRef
29.
Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J (2007) Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 55:1–14PubMedCrossRef
30.
Keum JS, Kong G, Yang SC, Shin DH, Park SS, Lee JH, Lee JD (1999) Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer 81:127–132PubMedCrossRef
31.
Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207–210PubMedCrossRef
32.
Wachi S, Yoneda K, Wu R (2005) Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 21:4205–4208. GEO accession GDS 1312
33.
Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP et al (2005) Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 166:1827–1840. GEO accession GDS 1220
34.
Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM et al (2006) Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66:7466–7472. GEO accession GDS 2373
35.
Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr et al (2005) Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 167:1763–1775. GEO accession GDS 1650
36.
Beskow C, Skikuniene J, Holgersson A, Nilsson B, Lewensohn R, Kanter L, Viktorsson K (2009) Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br J Cancer 101:816–821PubMedCrossRef
37.
Chen HL, Gabrilovich D, Tampé R, Girgis KR, Nadaf S, Carbone DP (1996) A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 13:210–213PubMedCrossRef
38.
Ewen ME, Lamb J (2004) The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 10:158–162PubMedCrossRef
39.
Knudsen KE, Diehl JA, Haiman CA, Knudsen ES (2006) Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25:1620–1628PubMedCrossRef
40.
Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812–1817PubMed
41.
Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS et al (2003) A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114:323–334PubMedCrossRef
42.
Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N et al (1994) PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 84:2726–2732PubMed
43.
Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS (1999) Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 59:2470–2476PubMed
44.
Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, Cai Z, Yi Q (2009) Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 23:1320–1328PubMedCrossRef
45.
Vilenchik MM, Knudson AG (2003) Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci USA 100:12871–12876PubMedCrossRef
46.
47.
Bernstein C, Bernstein H, Payne CM, Garewal H (2002) DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 511:145–178PubMedCrossRef
48.
Lieber MR, Ma Y, Pannicke U, Schwarz K (2003) Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 4:712–720PubMedCrossRef
49.
Zhao HJ, Hosoi Y, Miyachi H, Ishii K, Yoshida M, Nemoto K et al (2000) DNA-dependent protein kinase activity correlates with Ku70 expression and radiation sensitivity in esophageal cancer cell lines. Clin Cancer Res 6:1073–1078PubMed
50.
Xing J, Wu X, Vaporciyan AA, Spitz MR, Gu J (2008) Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer 112:2756–2764PubMedCrossRef
51.
Sirzén F, Nilsson A, Zhivotovsky B, Lewensohn R (1999) DNA-dependent protein kinase content and activity in lung carcinoma cell lines: correlation with intrinsic radiosensitivity. Eur J Cancer 35:111–116PubMedCrossRef
52.
Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S (2002) Towards patient-specific tumor antigen selection for vaccination. Immunol Rev 188:164–176PubMedCrossRef
53.
Aptisauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F (2007) Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 601:123–131CrossRef
54.
Méndez R, Rodríguez T, Del Campo A, Monge E, Maleno I, Aptsiauri N et al (2008) Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother 57:719–729PubMedCrossRef
55.
Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumor growth. Immunol Today 21:455–464PubMedCrossRef
56.
Seliger B, Höhne A, Knuth A, Bernhard H, Ehring B, Tampé R, Huber C (1996) Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 8:1427–1433
57.
Fruci D, Ferracuti S, Limongi MZ, Cunsolo V, Giorda E, Fraioli R et al (2006) Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines. J Immunol 176:4869–4879PubMed
Metadata
Title
Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer
Authors
Anneke Neumann
Helen Hörzer
Nina Hillen
Karin Klingel
Barbara Schmid-Horch
Hans-Jörg Bühring
Hans-Georg Rammensee
Hermann Aebert
Stefan Stevanović
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 9/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-013-1454-2

Other articles of this Issue 9/2013

Cancer Immunology, Immunotherapy 9/2013 Go to the issue

Original Article

Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer

Original Article

Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue

Original Article

CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis

Original Article

Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients

Original Article

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

Original Article

Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits